Tempest Therapeutics (TPST) Competitors $10.27 -0.51 (-4.73%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$10.01 -0.26 (-2.58%) As of 10/10/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. CRBP, MCRB, MIST, AVTX, SAVA, ELDN, PEPG, GNLX, IXHL, and ACTUShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Corbus Pharmaceuticals (CRBP), Seres Therapeutics (MCRB), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Cassava Sciences (SAVA), Eledon Pharmaceuticals (ELDN), PepGen (PEPG), Genelux (GNLX), Incannex Healthcare (IXHL), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Its Competitors Corbus Pharmaceuticals Seres Therapeutics Milestone Pharmaceuticals Avalo Therapeutics Cassava Sciences Eledon Pharmaceuticals PepGen Genelux Incannex Healthcare Actuate Therapeutics Corbus Pharmaceuticals (NASDAQ:CRBP) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Which has higher valuation & earnings, CRBP or TPST? Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$40.21M-$4.76-3.26Tempest TherapeuticsN/AN/A-$41.84M-$14.59-0.70 Does the media refer more to CRBP or TPST? In the previous week, Tempest Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Tempest Therapeutics and 4 mentions for Corbus Pharmaceuticals. Tempest Therapeutics' average media sentiment score of 0.63 beat Corbus Pharmaceuticals' score of 0.62 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in CRBP or TPST? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 3.6% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is CRBP or TPST more profitable? Corbus Pharmaceuticals' return on equity of -43.65% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -43.65% -39.62% Tempest Therapeutics N/A -334.76%-130.63% Do analysts prefer CRBP or TPST? Corbus Pharmaceuticals presently has a consensus target price of $45.43, indicating a potential upside of 192.33%. Tempest Therapeutics has a consensus target price of $30.00, indicating a potential upside of 192.11%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Tempest Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more volatility & risk, CRBP or TPST? Corbus Pharmaceuticals has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.08, indicating that its share price is 308% less volatile than the S&P 500. SummaryCorbus Pharmaceuticals beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.87M$2.65B$6.10B$10.63BDividend YieldN/A56.72%5.67%4.71%P/E Ratio-0.7022.9185.2726.57Price / SalesN/A745.20612.78132.59Price / CashN/A179.8938.5062.09Price / Book1.815.3712.726.53Net Income-$41.84M$32.78M$3.30B$275.96M7 Day Performance-1.25%2.02%0.89%-0.77%1 Month Performance-4.11%7.68%6.29%3.67%1 Year Performance-22.93%-1.76%80.41%37.30% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics2.0992 of 5 stars$10.27-4.7%$30.00+192.1%-28.2%$47.87MN/A-0.7020News CoverageAnalyst ForecastCRBPCorbus Pharmaceuticals3.9247 of 5 stars$14.52-2.1%$45.43+212.9%-15.2%$181.74MN/A-3.0540Analyst ForecastMCRBSeres Therapeutics2.1409 of 5 stars$21.00+2.0%$14.33-31.7%+24.2%$180.26M$126.32M-4.57330Analyst ForecastMISTMilestone Pharmaceuticals2.2171 of 5 stars$2.12+0.5%$4.50+112.3%+35.4%$179.34M$1M-2.5230News CoverageAnalyst ForecastAVTXAvalo Therapeutics3.2151 of 5 stars$14.00+4.5%$31.67+126.2%+37.7%$176.24M$440K0.0040Positive NewsSAVACassava Sciences2.495 of 5 stars$3.57-1.7%$2.00-44.0%-85.0%$175.36MN/A-1.4030Analyst ForecastELDNEledon Pharmaceuticals2.1291 of 5 stars$2.86+0.7%$10.00+249.7%+1.9%$170.06MN/A-2.4410News CoveragePositive NewsAnalyst ForecastPEPGPepGen3.4227 of 5 stars$4.96-3.3%$8.40+69.4%-45.6%$168.26MN/A-1.6830Analyst ForecastGap DownGNLXGenelux1.2588 of 5 stars$4.54+2.0%$20.33+347.9%+93.5%$168.09M$10K-5.2810News CoveragePositive NewsAnalyst ForecastIXHLIncannex Healthcare0.7202 of 5 stars$0.44-7.7%N/A-75.4%$167.52M$90K-0.373News CoverageAnalyst ForecastGap UpACTUActuate Therapeutics1.8791 of 5 stars$7.02+0.6%$20.33+189.6%+8.8%$162.24MN/A0.0010Analyst Forecast Related Companies and Tools Related Companies CRBP Alternatives MCRB Alternatives MIST Alternatives AVTX Alternatives SAVA Alternatives ELDN Alternatives PEPG Alternatives GNLX Alternatives IXHL Alternatives ACTU Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.